BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, Hadziyannis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10. [PMID: 9214471 DOI: 10.1002/hep.510260127] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Li B, Zhao H, Wu P, Wu Q, Chen K, Mu Y. A systematic review and meta-analysis of endocrine-related adverse events associated with interferon. Front Endocrinol 2022;13:949003. [DOI: 10.3389/fendo.2022.949003] [Reference Citation Analysis]
2 Shao YY, Cheng AL, Hsu CH. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist 2021;26:422-6. [PMID: 33687750 DOI: 10.1002/onco.13755] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zhang Y, Lin F, Tu W, Zhang J, Choudhry AA, Ahmed O, Cheng J, Cui Y, Liu B, Dai M, Chen L, Han D, Fan Y, Zeng Y, Li W, Li S, Chen X, Shen M, Pan P; medical team from Xiangya Hospital to support Hubei, China. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19. Mol Cell Endocrinol 2021;521:111097. [PMID: 33278491 DOI: 10.1016/j.mce.2020.111097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
4 Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, Guo Q, Arends P, Wang JY, Verhey E, de Knegt RJ, Xie Q, Janssen HLA. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). J Infect Dis 2017;215:1085-93. [PMID: 28329061 DOI: 10.1093/infdis/jix024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
5 Pastore F, Martocchia A, Stefanelli M, Prunas P, Giordano S, Toussan L, Devito A, Falaschi P. Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. World J Hepatol 2016; 8(2): 83-91 [PMID: 26807204 DOI: 10.4254/wjh.v8.i2.83] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
6 Suvak B, Dulger AC, Aykaç MC, Gonullu H, Gonullu E. Delta hepatitis-related thyroid disease: a unique phenomenon. Prz Gastroenterol 2015;10:169-72. [PMID: 26516384 DOI: 10.5114/pg.2015.49687] [Reference Citation Analysis]
7 Narciso-Schiavon JL, Schiavon LL. Autoantibodies in chronic hepatitis C: A clinical perspective. World J Hepatol 2015; 7(8): 1074-1085 [PMID: 26052396 DOI: 10.4254/wjh.v7.i8.1074] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
8 Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res 2014;24:150-7. [PMID: 24509407 DOI: 10.1097/CMR.0000000000000050] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
9 Melo LO, Monteiro DL, Rodrigues NC. Factors associated with treatment interruption for Hepatitis C. Rev Assoc Med Bras (1992) 2014;60:29-34. [PMID: 24918849 DOI: 10.1590/1806-9282.60.01.008] [Reference Citation Analysis]
10 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2007;3:469-76. [PMID: 24395487 DOI: 10.1007/s11908-007-1004-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Calvaruso V, Craxì A. Immunological alterations in hepatitis C virus infection. World J Gastroenterol 2013; 19(47): 8916-8923 [PMID: 24379616 DOI: 10.3748/wjg.v19.i47.8916] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
12 Zignego AL, Gragnani L, Giannini C, Laffi G. The hepatitis C virus infection as a systemic disease. Intern Emerg Med. 2012;7 Suppl 3:S201-S208. [PMID: 23073858 DOI: 10.1007/s11739-012-0825-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
13 Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 2013;23:1345-66. [PMID: 23750887 DOI: 10.1089/thy.2013.0241] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
14 Sundquist K, Sundquist J, Ji J. Risk of hepatocellular carcinoma and cancers at other sites among patients diagnosed with chronic hepatitis B virus infection in Sweden. J Med Virol. 2014;86:18-22. [PMID: 24038002 DOI: 10.1002/jmv.23754] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
15 Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA; PEDS-C Clinical Research Network. Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2013;56:304-10. [PMID: 23439301 DOI: 10.1097/MPG.0b013e3182774cae] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
16 Mammen JS, Ghazarian SR, Rosen A, Ladenson PW. Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C. Thyroid 2013;23:1151-8. [PMID: 23517287 DOI: 10.1089/thy.2012.0565] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
17 Slim J, Afridi MS. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV. Infect Dis Clin North Am 2012;26:917-29. [PMID: 23083824 DOI: 10.1016/j.idc.2012.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
18 Himoto T, Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. Auto Immun Highlights. 2013;4:39-53. [PMID: 26000142 DOI: 10.1007/s13317-013-0046-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
19 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
20 Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 2013;8:e55364. [PMID: 23383326 DOI: 10.1371/journal.pone.0055364] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
21 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401] [Reference Citation Analysis]
22 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
23 Himoto T, Masaki T. Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol. 2012;2012:871401. [PMID: 22988469 DOI: 10.1155/2012/871401].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Mammen JS, Ghazarian SR, Pulkstenis E, Subramanian GM, Rosen A, Ladenson PW. Phenotypes of Interferon-α-Induced Thyroid Dysfunction among Patients Treated for Hepatitis C Are Associated with Pretreatment Serum TSH and Female Sex. The Journal of Clinical Endocrinology & Metabolism 2012;97:3270-6. [DOI: 10.1210/jc.2012-1026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
25 Vergani D, Mieli-Vergani G. Autoimmune manifestations in viral hepatitis. Semin Immunopathol. 2013;35:73-85. [PMID: 23010889 DOI: 10.1007/s00281-012-0328-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
26 Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 2011;103:1572-87. [PMID: 22010182 DOI: 10.1093/jnci/djr373] [Cited by in Crossref: 104] [Cited by in F6Publishing: 72] [Article Influence: 9.5] [Reference Citation Analysis]
27 Said A, Elbahrawy A, Alfiomy M, Abdellah M, Shahat K, Salah M, Mostafa S, Elwassief A, Aboelfotoh A, Abdelhafeez H, El-Sherif A. Pegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient. BMJ Case Rep 2011;2011:bcr0620114400. [PMID: 22688484 DOI: 10.1136/bcr.06.2011.4400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
28 Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf 2011;10:429-35. [PMID: 21323500 DOI: 10.1517/14740338.2011.559161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
29 Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, Ferraz ML, Silva AE. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop 2010;43:217-23. [PMID: 20563484 DOI: 10.1590/s0037-86822010000300001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
30 Lee YN, Jeong SW, Lim JH, Ryu YS, Jeon SR, Kim SK, Jang JY, Kim YS, Kim BS, Roh MO. [Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C]. Korean J Hepatol. 2010;16:187-191. [PMID: 20606504 DOI: 10.3350/kjhep.2010.16.2.187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Yang JF, Kao YH, Dai CY, Huang JF, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Yu ML. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatol Int 2010;4:732-40. [PMID: 21286344 DOI: 10.1007/s12072-010-9208-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
32 Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol. 2010;24:183-192. [PMID: 20227031 DOI: 10.1016/j.bpg.2009.10.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
33 Menconi F, Hasham A, Tomer Y. Environmental triggers of thyroiditis: hepatitis C and interferon-α. J Endocrinol Invest 2011;34:78-84. [PMID: 21297381 DOI: 10.1007/BF03346699] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
34 Jamil KM, Leedman PJ, Kontorinis N, Tarquinio L, Nazareth S, McInerney M, Connelly C, Flexman J, Burke V, Metcalf C. Interferon-induced thyroid dysfunction in chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:1017-1023. [PMID: 19054259 DOI: 10.1111/j.1440-1746.2008.05690.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
35 Hass HG, Klein R, Nehls O, Kaiser S. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1). J Clin Gastroenterol. 2009;43:470-476. [PMID: 19247202 DOI: 10.1097/mcg.0b013e318184a470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
36 Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves’ disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res Clin Pract. 2009;86:e19-e21. [PMID: 19744739 DOI: 10.1016/j.diabres.2009.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
37 Sarzi-puttini P, Doria A. Organ specific-autoantibodies: Their role as markers and predictors of disease: Editorial. Autoimmunity 2009;41:1-10. [DOI: 10.1080/08916930701619136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
38 Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J Gastroenterol Hepatol 2009;24:1024-9. [PMID: 19383078 DOI: 10.1111/j.1440-1746.2009.05812.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
39 Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol 2009; 15(3): 328-333 [PMID: 19140232 DOI: 10.3748/wjg.15.328] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
40 Hashemi N, Rossi S, Navarro VJ, Herrine SK. Safety of peginterferon in the treatment of chronic hepatitis C. Expert Opin Drug Saf. 2008;7:771-781. [PMID: 18983223 DOI: 10.1517/14740330802423291] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
41 Mcdonald ND, Pender MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Australian and New Zealand Journal of Medicine 2000;30:278-9. [DOI: 10.1111/j.1445-5994.2000.tb00823.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
42 Rodríguez-torres M, Ríos-bedoya CF, Ortiz-lasanta G, Marxuach-cuétara AM, Jiménez-rivera J. Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Annals of Hepatology 2008;7:72-7. [DOI: 10.1016/s1665-2681(19)31891-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
43 Larrey D, Couzigou P, Denis J. Hépatite chronique C : gestion des effets indésirables du traitement. Gastroentérologie Clinique et Biologique 2007;31:20-8. [DOI: 10.1016/s0399-8320(07)92559-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
44 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
45 Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, Lachkar H, Benaïssa A. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris). 2006;67:343-347. [PMID: 17072240 DOI: 10.1016/s0003-4266(06)72609-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
46 Doyle MK, Berggren R, Magnus JH. Interferon-Induced Sarcoidosis. JCR: Journal of Clinical Rheumatology 2006;12:241-8. [DOI: 10.1097/01.rhu.0000240035.67652.9d] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
47 Andrade R. Manejo de los efectos adversos del tratamiento. Gastroenterología y Hepatología 2006;29:184-9. [DOI: 10.1157/13097657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
48 Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB;  Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39:2-17. [PMID: 16884964 DOI: 10.1016/j.dld.2006.06.008] [Cited by in Crossref: 164] [Cited by in F6Publishing: 151] [Article Influence: 10.3] [Reference Citation Analysis]
49 Russo S, Kema IP, Haagsma EB, Boon JC, Willemse PH, den Boer JA, de Vries EG, Korf J. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med 2005;67:773-7. [PMID: 16204437 DOI: 10.1097/01.psy.0000171193.28044.d8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
50 Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, Ferrannini E. Thyroid Disorders in Chronic Hepatitis C Virus Infection. Thyroid 2006;16:563-72. [DOI: 10.1089/thy.2006.16.563] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 5.0] [Reference Citation Analysis]
51 Kee K, Lee C, Wang J, Tung H, Changchien C, Lu S, Wang P. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis. Journal of Gastroenterology and Hepatology 2006;21:319-26. [DOI: 10.1111/j.1440-1746.2006.03947.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Deutsch M, Koskinas J, Tzannos K, Vassilopoulos D, Mailis A, Tolis G, Hadziyannis S. Hashimoto Encephalopathy with Pegylated Interferon Alfa-2b and Ribavirin. Ann Pharmacother 2005;39:1745-8. [DOI: 10.1345/aph.1g144] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
53 Moncoucy X, Leymarie F, Delemer B, Lévy S, Bernard-Chabert B, Bouché O, Jolly D, Diebold MD, Cadiot G, Thiéfin G. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol 2005;29:339-45. [PMID: 15864192 DOI: 10.1016/s0399-8320(05)80778-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
54 Lin YQ, Wang X, Murthy MS, Agarwala S. Life-Threatening Thyrotoxicosis Induced by Combination Therapy with Peg-Interferon and Ribavirin in Chronic Hepatitis C. Endocrine Practice 2005;11:135-9. [DOI: 10.4158/ep.11.2.135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
55 Loftis JM, Wall JM, Linardatos E, Benvenga S, Hauser P. A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C. J Endocrinol Invest. 2004;27:RC16-RC20. [PMID: 15505982 DOI: 10.1007/BF03347491] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
56 Oppenheim Y, Ban Y, Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmun Rev. 2004;3:388-393. [PMID: 15288006 DOI: 10.1016/j.autrev.2004.03.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
57 Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longombardo G, Fadda P, Pampana A, Maccheroni M, Ferrannini E. Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia. QJM. 2004;97:499-506. [PMID: 15256607 DOI: 10.1093/qjmed/hch088] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
58 Medina J, García-Buey L, Moreno-Otero R. Hepatitis C virus-related extra-hepatic disease--aetiopathogenesis and management. Aliment Pharmacol Ther. 2004;20:129-141. [PMID: 15233692 DOI: 10.1111/j.1365-2036.2004.01919.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
59 Fox RK. Hepatitis C virus outside the liver. Curr hepatitis rep 2003;2:116-24. [DOI: 10.1007/s11901-003-0005-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
60 Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719. [PMID: 12761728 DOI: 10.1016/s0016-5085(03)00394-9] [Cited by in Crossref: 185] [Cited by in F6Publishing: 181] [Article Influence: 9.7] [Reference Citation Analysis]
61 Prummel MF, Laurberg P. Interferon-α and Autoimmune Thyroid Disease. Thyroid 2003;13:547-51. [DOI: 10.1089/105072503322238809] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 7.4] [Reference Citation Analysis]
62 Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci. 2003;325:135-148. [PMID: 12640289 DOI: 10.1097/00000441-200303000-00006] [Cited by in Crossref: 94] [Cited by in F6Publishing: 84] [Article Influence: 4.9] [Reference Citation Analysis]
63 Ward DL, Bing-You RG. Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract 2001;7:52-8. [PMID: 11250770 DOI: 10.4158/EP.7.1.52] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
64 Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36:S226-S236. [PMID: 12407598 DOI: 10.1002/hep.1840360729] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
65 Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36:S226-36. [PMID: 12407598 DOI: 10.1053/jhep.2002.36991] [Cited by in Crossref: 9] [Cited by in F6Publishing: 26] [Article Influence: 0.5] [Reference Citation Analysis]
66 Papo T. Interferon alpha et auto-immunité. La Revue de Médecine Interne 2002;23:501S-10S. [DOI: 10.1016/s0248-8663(02)00666-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
67 Chu JW, Kao PN, Faul JL, Doyle RL. High Prevalence of Autoimmune Thyroid Disease in Pulmonary Arterial Hypertension. Chest 2002;122:1668-73. [DOI: 10.1378/chest.122.5.1668] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 4.9] [Reference Citation Analysis]
68 Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs. 2002;62:507-556. [PMID: 11827565 DOI: 10.2165/00003495-200262030-00009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
69 Ramos-casals M, García-carrasco M, Font Franco J, Ingelmo Morín M. Manifestaciones clínicas e inmunológicas asociadas a la infección crónica por el virus de la hepatitis C. Revista Clínica Española 2002;202:224-32. [DOI: 10.1016/s0014-2565(02)71033-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21:225-232. [PMID: 11454184 DOI: 10.1034/j.1600-0676.2001.021004225.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 116] [Article Influence: 5.9] [Reference Citation Analysis]
71 Sulkowski MS. Hepatitis C virus infection in HIV-infected patients. Curr Infect Dis Rep 2001;3:469-76. [DOI: 10.1007/bf03160472] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
72 Marinho RT, Johnson NW, Fatela NM, Serejo FS, Glória H, Raimundo MO, Velosa JF, Ramalho FJ, Moura MC. Oropharyngeal pemphigus in a patient with chronic hepatitis C during interferon alpha-2a therapy. Eur J Gastroenterol Hepatol. 2001;13:869-872. [PMID: 11474319 DOI: 10.1097/00042737-200107000-00017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
73 Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, O'Keane JC, Crowe J. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001;49:423-30. [PMID: 11511566 DOI: 10.1136/gut.49.3.423] [Cited by in Crossref: 111] [Cited by in F6Publishing: 107] [Article Influence: 5.3] [Reference Citation Analysis]
74 Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. [PMID: 11171829 DOI: 10.1136/gut.48.3.378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
75 Piquer S, Hernández C, Enriquez J, Ross A, Esteban JI, Genescà J, Bonifacio E, Puig-Domingo M, Simó R. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med. 2001;137:38-42. [PMID: 11150022 DOI: 10.1067/mlc.2001.111515] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
76 Hadziyannis SJ, Vassilopoulos D. Complex management issues: management of HCV in the atypical patient. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:277-291. [PMID: 10890322 DOI: 10.1053/bega.1999.0076] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
77 Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol. 2000;30:125-143. [PMID: 10730918 DOI: 10.1097/00004836-200003000-00005] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 4.0] [Reference Citation Analysis]
78 Curry MP, Golden-Mason L, Nolan N, Parfrey NA, Hegarty JE, O'Farrelly C. Expansion of peripheral blood CD5+ B cells is associated with mild disease in chronic hepatitis C virus infection. J Hepatol 2000;32:121-5. [PMID: 10673076 DOI: 10.1016/s0168-8278(00)80198-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
79 Broussolle C, Steineur MP, Bailly F, Zoulim F, Trépo C. [Hepatitis C virus infection and thyroid diseases]. Rev Med Interne. 1999;20:766-773. [PMID: 10522298 DOI: 10.1016/s0248-8663(00)88683-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
80 Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf). 1999;50:503-509. [PMID: 10468911 DOI: 10.1046/j.1365-2265.1999.00686.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 2.9] [Reference Citation Analysis]
81 Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother. 1999;53:242-254. [PMID: 10424246 DOI: 10.1016/s0753-3322(99)80095-x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 3.0] [Reference Citation Analysis]
82 Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol. 1999;30:794-800. [PMID: 10365804 DOI: 10.1016/s0168-8278(99)80131-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 1.9] [Reference Citation Analysis]
83 Minelli R, Braverman LE, Valli MA, Schianchi C, Pedrazzoni M, Fiaccadori F, Salvi M, Magotti MG, Roti E. Recombinant interferon alpha (rIFN-alpha) does not potentiate the effect of iodine excess on the development of thyroid abnormalities in patients with HCV chronic active hepatitis. Clin Endocrinol (Oxf) 1999;50:95-100. [PMID: 10341861 DOI: 10.1046/j.1365-2265.1999.00616.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
84 Zauli D, Cassani F, Bianchi F. Auto-antibodies in hepatitis C. Biomedicine & Pharmacotherapy 1999;53:234-41. [DOI: 10.1016/s0753-3322(99)80094-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
85 Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999;44:754-8. [PMID: 10205219 DOI: 10.1136/gut.44.5.754] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 4.5] [Reference Citation Analysis]
86 Durelli L, Ferrero B, Oggero A, Verdun E, Bongioanni M, Gentile E, Isoardo G, Ricci A, Rota E, Bergamasco B, Durazzo M, Saracco G, Biava M, Brossa P, Giorda L, Pagni R, Aimo G. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. Journal of the Neurological Sciences 1999;162:74-83. [DOI: 10.1016/s0022-510x(98)00299-8] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 2.5] [Reference Citation Analysis]
87 Martin TG, Shuman MA. Interferon-induced thrombocytopenia: is it time for thrombopoietin. Hepatology 1998;28:1430-2. [PMID: 9794932 DOI: 10.1002/hep.510280536] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]